The effect of benralizumab on inflammation in severe asthma: a real-life analysis
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on a...
Saved in:
| Main Authors: | Dina Visca, Francesco Ardesi, Martina Zappa, Sarah Grossi, Patrizia Pignatti, Marco Vanetti, Laura Pini, Giovanni Sotgiu, Rosella Centis, Giovanni Battista Migliori, Antonio Spanevello |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/17534666241304685 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eosinophils in chronic obstructive pulmonary disease
by: Marco Vanetti, et al.
Published: (2025-05-01) -
Post-tuberculosis lung disease patients benefit from vaccinations as other respiratory conditions
by: Giovanni Battista Migliori, et al.
Published: (2025-05-01) -
Factors influencing the real-world effectiveness of benralizumab in uncontrolled asthma
by: María Del Mar Sánchez Suárez, et al.
Published: (2025-07-01) -
TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01) -
Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis
by: Mahdis Cheraghi, et al.
Published: (2025-03-01)